EAGLE PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (the “Agreement”) is made as of , by and between Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This DEVELOPMENT AND LICENSE AGREEMENT (this “AGREEMENT”) is made as of February 13, 2009 (the “EFFECTIVE DATE”) by and between Robert One, LLC, having its principal place of business at 123 Blackberry Lane, Amherst, MA 01002 (“ROBERT”), and Eagle Pharmaceuticals, Inc. having its principal place of business at 470 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“EAGLE”). ROBERT and EAGLE may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This SUPPLY AND DISTRIBUTION AGREEMENT (“Agreement”), dated as of January 28, 2013, is made by and between Eagle Pharmaceuticals, Inc., a Delaware corporation with its principal offices located at 470 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677 (“Eagle”), and Sandoz AG, a Swiss corporation with a corporate address at Lichtstraße 35, CH 4056 Basel, Switzerland (“Sandoz”).
DEVELOPMENT AND LICENSE AGREEMENTOriginal Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Development and License Agreement (“AGREEMENT”) is made and entered into June 12, 2007 (the “EFFECTIVE DATE”) by and between SciDose, LLC, having its principal place of business at 123 Blackberry Lane, Amherst, MA 01002 (“SCIDOSE”); and Eagle Pharmaceutical, Inc. having its principal place of business at 470 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“EAGLE”). SCIDOSE and EAGLE may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This LICENSE AND DEVELOPMENT AGREEMENT (this “Agreement”), is entered into as of the Effective Date by and between THE MEDICINES COMPANY, a Delaware corporation located at 8 Sylvan Way, Parsippany, N.J. 07054 (“MDCO”), and EAGLE PHARMACEUTICALS, INC., a Delaware corporation located at 470 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677 (“Eagle”).
LICENSE AND SUBLICENSE AGREEMENT BETWEEN LYOTROPIC THERAPEUTICS, INC. AND EAGLE PHARMACEUTICALS, INC.License and Sublicense Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is made and entered into this 16th day of October, 2008 (the “Effective Date”), between Lyotropic Therapeutics, Inc., a Virginia corporation (“Lyotropic”), and Eagle Pharmaceuticals, Inc., a Delaware corporation (“Eagle”).
ContractQuality Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • England and Wales
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
EAGLE PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of April 11, 2013, by and among Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series A Convertible Preferred Stock listed on the Schedule of Investors attached hereto as Exhibit A (the “Series A Holders”), the holders of the Company’s Series B Convertible Preferred Stock listed on the Schedule of Investors attached hereto as Exhibit A (the “Series B Holders”), the holders of the Company’s Series B-1 Convertible Preferred Stock listed on the Schedule of Investors attached hereto as Exhibit A (the “Series B-1 Holders”), the holders of the Company’s Series C Convertible Preferred Stock listed on the Schedule of Investors attached hereto as Exhibit A (the “Series C Holders” and, collectively with the Series A Holders, the Series B Holders and the Series B-1 Holders, the “Investors”) and Scott L. Tarriff (the “Key Employee”).
SUPPLY AGREEMENTSupply Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SUPPLY AGREEMENT (the “Agreement”), dated as of September 24, 2009 (the “Effective Date”), is made by and between EAGLE PHARMACEUTICALS, INC., a Delaware corporation (“Eagle”), and THE MEDICINES COMPANY, a Delaware corporation (“MDCO”). Eagle and MDCO may be referred to herein individually as a “Party” and together as the “Parties”.
SHORT FORM LEASE Between MACK-CALI CHESTNUT RIDGE L.L.C., as Landlord, and EAGLE PHARMACEUTICALS, INC., as Tenant Building: Woodcliff Lake, New JerseyAgreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • December 20th, 2013 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Development and License Agreement (“AGREEMENT”) is made and entered into September 24, 2007 (the “EFFECTIVE DATE”) by and between SciDose, LLC, having its principal place of business at 123 Blackberry Lane, Amherst, MA 01002 (“SCIDOSE”), and Eagle Pharmaceutical, Inc. having its principal place of business at 470 Chestnut Ridge Road, Woodcliff Lake, NJ 07677 (“EAGLE”). SCIDOSE and EAGLE may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
